STAT3 and ovarian carcinoma: Specifically, Han et al. designed the novel oncolytic Ad-M4 targeting signal transducer and activator of transcription 3 (STAT3) in ovarian cancer and showed that the aberrant expression and constitutive activation of STAT3 were key factors in cisplatin resistance in both ovarian cancer cell lines and ovarian cancer tissues samples [43].